Pharvaris (NASDAQ:PHVS) Rating Reiterated by Morgan Stanley

Morgan Stanley reiterated their overweight rating on shares of Pharvaris (NASDAQ:PHVS) in a research note released on Monday morning, Benzinga reports. They currently have a $34.00 price target on the stock.

Other equities research analysts have also recently issued reports about the stock. Wedbush restated an outperform rating and set a $35.00 price objective on shares of Pharvaris in a research note on Thursday, April 11th. JMP Securities lifted their price objective on shares of Pharvaris from $49.00 to $50.00 and gave the company a market outperform rating in a research note on Thursday, April 11th.

Pharvaris Stock Performance

Shares of NASDAQ PHVS opened at $22.77 on Monday. Pharvaris has a fifty-two week low of $7.93 and a fifty-two week high of $33.00. The firm’s 50-day simple moving average is $23.55 and its 200 day simple moving average is $23.32.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, April 10th. The company reported ($0.80) earnings per share for the quarter. On average, sell-side analysts expect that Pharvaris will post -2.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

Hedge funds and other institutional investors have recently bought and sold shares of the business. Hudson Bay Capital Management LP bought a new stake in Pharvaris in the third quarter worth about $812,000. Walleye Capital LLC raised its position in Pharvaris by 15.2% in the third quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock worth $1,691,000 after acquiring an additional 10,691 shares in the last quarter. Blackstone Inc. bought a new stake in Pharvaris in the fourth quarter worth about $2,805,000. Vivo Capital LLC bought a new stake in Pharvaris in the fourth quarter worth about $7,994,000. Finally, Commodore Capital LP bought a new stake in Pharvaris in the fourth quarter worth about $22,440,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).